Peptech launches dog contraceptive

By Renate Krelle
Thursday, 09 December, 2004

Peptech Animal Health, a wholly owned subsidiary of Sydney-based Peptech (ASX:PTD) has begun to market its slow-release canine contraceptive, Suprelorin, to Australian veterinarians.

The Suprelorin implant is is inserted under the skin between the dog's shoulders . It contains an active ingredient, deslorelin, which causes temporary sterility and suppresses sexual behaviour by inactivating the pituitary-gland receptors for the master signalling molecule, gonadoptrophin-releasing hormone (GnRH). This reduces testosterone levels to zero.

"Castration is widely recommended in Australia and New Zealand, for good health and behavioural reasons," said Peptech Animal Health managing director, Dr Tim Trigg.

"Suprelorin provides the advantages of castration, without resorting to surgery."

Peptech Animal Health recently received an Australian Research Committee (ARC) linkage grant to investigate the use of Suprelorin in controlling large marsupial populations, including koala and kangaroo.

Related News

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd